Overview

Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria

Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
The aim of this non-interventional study is to assess oral vinorelbine dose schedules (initial dose, dose increase/maintenance/reduction) applied during the initial 8 weeks of treatment under routine conditions in Germany together with the underlying reasons for the respective chosen schedules.
Details
Lead Sponsor:
Pierre Fabre Pharma GmbH
Collaborator:
Winicker Norimed GmbH
Treatments:
Vinblastine
Vinorelbine